![](/img/cover-not-exists.png)
DOP41 Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies
Chiorean, M, Su, C, Matsuoka, K, Orlando, A, Thorpe, A J, Nduaka, C I, Chapman, D S, Woodworth, D A, Lawendy, N, Friedman, G S, Cohen, R DVolume:
13
Journal:
Journal of Crohn's and Colitis
DOI:
10.1093/ecco-jcc/jjy222.075
Date:
January, 2019
File:
PDF, 231 KB
2019